Eiger BioPharmaceuticals, Inc. (EIGRQ)
USD 8.5
(6.25%)
USD 8.5
(6.25%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -74.54 Million | -83.01 Million | -71.51 Million | -63.18 Million | -63.61 Million | -42.67 Million |
| Net Income | -74.96 Million | -96.77 Million | -33.91 Million | -65.05 Million | -70.25 Million | -52.39 Million |
| Depreciation & Amortization | 750 Thousand | 842 Thousand | 799 Thousand | 645 Thousand | 486 Thousand | 54 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 5 Million | 8.31 Million | 7.9 Million | 5.97 Million | 5.9 Million | - |
| Change in working capital | -5.73 Million | 481 Thousand | -1.34 Million | -5.89 Million | -9000.00 | 4.06 Million |
| Other non-cash items | 12.02 Million | 13.51 Million | -33.69 Million | 10.3 Million | 6.54 Million | 3.06 Million |
| Investing Cash Flow | 74.22 Million | 9.63 Million | 61.53 Million | -44.78 Million | -16.47 Million | -29.08 Million |
| Investments in PPE | -234 Thousand | -340 Thousand | -48.73 Million | -258 Thousand | -475 Thousand | -142 Thousand |
| Acquisitions | - | - | 281 Thousand | - | - | - |
| Investment purchases | -19.38 Million | -75.1 Million | -84.64 Million | -128.29 Million | -96.26 Million | -57.19 Million |
| Sales/Maturities of investments | 93.85 Million | 85.07 Million | 99.63 Million | 83.76 Million | 80.27 Million | 28.25 Million |
| Other Investing Activities | 74.46 Million | 9.97 Million | 95 Million | -44.52 Million | -15.99 Million | - |
| Financing Cash Flow | 41 Thousand | 76.95 Million | 3.34 Million | 97.46 Million | 58.19 Million | 100.98 Million |
| Debt repayment | - | -5.44 Million | - | - | -4.96 Million | -9.93 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 41 Thousand | 71.5 Million | 3.34 Million | 97.46 Million | 54.16 Million | 91.04 Million |
| Other Financing Activities | -15 Thousand | -1.4 Million | -491 Thousand | -22 Thousand | -932 Thousand | - |
| Accounts receivables | 84 Thousand | 828 Thousand | -2.57 Million | - | - | - |
| Accounts payables | -6.83 Million | 1.15 Million | 3.23 Million | -1.89 Million | 584 Thousand | 2.64 Million |
| Inventory | 1.62 Million | -1.36 Million | -2.42 Million | - | - | - |
| Other working capital | -608 Thousand | -132 Thousand | 425 Thousand | -3.99 Million | -593 Thousand | 1.41 Million |
| Cash at beginning of period | 25.79 Million | 22.22 Million | 28.86 Million | 39.37 Million | 61.26 Million | 32.03 Million |
| Cash at end of period | 25.44 Million | 25.79 Million | 22.22 Million | 28.86 Million | 39.37 Million | 61.26 Million |
| Capital Expenditure | -234 Thousand | -340 Thousand | -48.73 Million | -258 Thousand | -475 Thousand | -142 Thousand |
| Effect of forex changes on cash | -79 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | -358 Thousand | 3.57 Million | -6.64 Million | -10.5 Million | -21.88 Million | 29.22 Million |
| Free Cash Flow | -74.78 Million | -83.35 Million | -120.24 Million | -63.44 Million | -64.08 Million | -42.81 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -13.45 Million | -74.96 Million | -18.03 Million | -20.69 Million | -22.78 Million | -96.77 Million |
| Depreciation & Amortization | 180 Thousand | 750 Thousand | 198 Thousand | 183 Thousand | 189 Thousand | 842 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 683 Thousand | 5 Million | 1.03 Million | 745 Thousand | 2.54 Million | 8.31 Million |
| Change in working capital | -1.67 Million | -5.73 Million | 2.12 Million | -2.22 Million | -3.95 Million | 481 Thousand |
| Other non-cash items | 5.01 Million | 12.02 Million | 282 Thousand | 2.37 Million | 4.35 Million | 13.51 Million |
| Investing Cash Flow | 11.99 Million | 74.22 Million | 19 Million | 29.84 Million | 13.38 Million | 9.63 Million |
| Investments in PPE | -1000.00 | -234 Thousand | - | -17 Thousand | -216 Thousand | -340 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -19.38 Million | - | - | -19.38 Million | -75.1 Million |
| Sales/Maturities of investments | 12 Million | 93.85 Million | 19 Million | 29.86 Million | 32.98 Million | 85.07 Million |
| Other Investing Activities | 12 Million | 74.46 Million | 19 Million | 29.86 Million | 13.59 Million | 9.97 Million |
| Financing Cash Flow | 7000.00 | 41 Thousand | 15 Thousand | -22 Thousand | 41 Thousand | 76.95 Million |
| Debt repayment | - | - | - | - | - | -5.44 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 7000.00 | 41 Thousand | 15 Thousand | -22 Thousand | 41 Thousand | 71.5 Million |
| Other Financing Activities | 7000.00 | -15 Thousand | 15 Thousand | -22 Thousand | 41 Thousand | -1.4 Million |
| Accounts receivables | -337 Thousand | 84 Thousand | 2.38 Million | 171 Thousand | -2.13 Million | 828 Thousand |
| Accounts payables | -2.67 Million | -6.83 Million | -202 Thousand | -5.5 Million | 1.55 Million | 1.15 Million |
| Inventory | -637 Thousand | 1.62 Million | -908 Thousand | 4.03 Million | -860 Thousand | -1.36 Million |
| Other working capital | 1.97 Million | -608 Thousand | 852 Thousand | -918 Thousand | -2.51 Million | -132 Thousand |
| Cash at beginning of period | 27.5 Million | 25.79 Million | 22.98 Million | 15.18 Million | 25.79 Million | 22.22 Million |
| Cash at end of period | 25.44 Million | 25.44 Million | 27.5 Million | 22.98 Million | 15.18 Million | 25.79 Million |
| Capital Expenditure | -1000.00 | -234 Thousand | - | -17 Thousand | -216 Thousand | -340 Thousand |
| Effect of forex changes on cash | -113 Thousand | -79 Thousand | 57 Thousand | 13 Thousand | -36 Thousand | - |
| Net cash flow / Change in cash | -2.06 Million | -358 Thousand | 4.51 Million | 7.8 Million | -10.61 Million | 3.57 Million |
| Free Cash Flow | -13.95 Million | -74.78 Million | -14.55 Million | -22.05 Million | -24.22 Million | -83.35 Million |
SIS
BAESF
NSARO
600375
0ITS
PEBO